Furthermore, shares are no longer trading at or
around cash per share.
Not exact matches
He points out that the company's business model allows it to turn its inventory
around about twice as many times as its peers and its strong free
cash flow — the company has about $ 4 of
cash per share, he says — could be used to buy back stocks, which it has done in the past.
This includes $ 24.05
per share in
cash and $ 9.10 worth of a tracking stock for VMWare (VMW), an EMC - owned cloud and virtualization software company that already has
around a 20 % equity «stub» trading on the public markets.
The new bid had been
around 7 % higher than Pfizer's original approach, and would have provided AstraZeneca stockholders with
around $ 84
per share in
cash and stock. www.astrazeneca.com
The company currently holds about $ 80 billion in
cash overseas, which translates to
around $ 115
per share.
If you had used your $ 1.50
per share in
cash dividends to buy more stock, you could have theoretically increased your total
share ownership position by
around 2 percent if you did it through a low - cost dividend reinvestment program or a broker that didn't charge for the service.
In 2004, Microsoft paid out $ 32 billion of its $ 50 billion in
cash in a one - time $ 3
per share dividend when the stock was trading at
around $ 29.
We estimate the
cash to be paid at
around $ 1.22
per share (BVF estimates the amount at $ 1.20
per share), which is more than 60 % higher than AVGN's $ 0.76 close Wednesday.
We estimate AVGN's
cash at
around $ 1.22
per share (BVF estimates $ 1.20
per share), which is
around 40 % higher than AVGN's $ 0.86 close Friday.
We estimate AVGN's
cash at
around $ 1.22
per share, which is more than 60 % higher than AVGN's $ 0.76 close Wednesday.
Its liquidating value is predominantly
cash, so much so that MEMS has net
cash of
around $ 62M or $ 2.60
per share, which is
around 60 % higher than its stock price.
Our estimate of MATH's liquidation value is its net
cash value after deducting
around $ 2M of
cash burn, professional fees and other liquidation costs, or
around $ 11.7 M or $ 1.27
per share.
We estimate MATH's net
cash value to be
around $ 11.7 M or $ 1.27
per share.
In the past decades, earnings
per share and dividend grew decently
around 5 %
per year which makes the business a stable
cash generation machine.
While BVF's slate was not successful at the special meeting, AVGN's board now plans to develop its own plan of liquidation, which should put a floor on AVGN's stock at
around its net
cash value of $ 37M or $ 1.24
per share less wind down costs.
Around the same time the CIT deal was playing out, Klarman took a sizable stake in Facet Biotech — a small biotech company spun off in December 2008 from PDL BioPharma — for an average cost of $ 9 even though it had $ 17
per share in net
cash at the time of the spinoff.
The company has
around $ 49.7 M or $ 0.48
per share in
cash and a further $ 12.6 M or $ 0.12
per share in restricted
cash.
$ 10.5 M off the
cash reduces SOAP's net
cash value to
around $ 76M or $ 4.95
per share.
At the time the stock traded
around $ 2, which was below
cash value
per share.
The company's net
cash value is
around $ 15.6 M or $ 0.82
per share.
The impact of a $ 2M stock buyback at Friday's closing price is to increase
per share liquidation value by
around 6 % to $ 1.64 and leaves the company with $ 26.3 M in
cash and short term investments.
Meanwhile the
cash hoard is building and the market is beginning to notice; the
share price has finally moved up from the mid / upper 20's to
around $ 34
per share with the latest announcements and is now trading for just over 80 % of stated book value and 88 % of post transaction
cash value.
From the Form 10 it looked like book value was going be
around $ 48
per share with about half of that in cold hard
cash.
The company's net
cash value is
around $ 16M or $ 0.85
per share, which means the company is trading at a small premium to its net
cash.
We estimate the net
cash value to be
around $ 20.6 M or $ 1.57
per share and the liquidation value to be
around $ 23.2 M or $ 1.77
per share.
We estimate AVGN's
cash at
around $ 1.22
per share (BVF estimates $ 1.20
per share), which is
around 20 % higher than AVGN's $ 1.02 close today.
The company could comfortably pay a special dividend of
around $ 2.75
per share and still leave $ 40M of
cash in the bank.
At its $ 2.10 close yesterday, it's trading at
around 80 % of $ 2.65
per share liquidating value, most of which is in
cash and equivalents and other liquid current assets.
I initially estimated the net
cash value to be
around $ 22.2 M or $ 2.20
per share.
We estimate the company's net
cash value to be
around $ 26.5 M or $ 0.80
per share.
We estimate the net
cash value to be
around 75 % higher at $ 42.6 M or $ 1.60
per share.
While BVF's slate was unsuccessful at the special meeting, AVGN's board has developed its own plan of liquidation, which should put a floor on AVGN's stock at
around its net
cash value of $ 34M or $ 1.14
per share less wind down costs.
We've now reduced our estimate of the net
cash value to
around $ 32.2 M or $ 1.23
per share and the liquidation value to
around $ 43.4 M or $ 1.65
per share.
We estimate that value to be
around 38 % higher still at $ 24.3 M or $ 0.54
per share and ABTL's net
cash value to be
around $ 15.4 M or $ 0.34
per share.
We initially estimated the company's net
cash value to be
around $ 27.7 M or $ 0.84
per share.
We estimate the company's liquidation value to be
around $ 171.6 M or $ 5.74
per share, which is predominantly
cash and equivalents in the amount of $ 172M or $ 5.75
per share.
We last estimated CRGN's net
cash value to be
around $ 59.9 M or $ 1.05
per share.
We estimate the net
cash value to be
around $ 22.2 M or $ 2.20
per share.
With total liabilities of only $ 3.9 M or $ 0.15
per share, NSTR had a net
cash value in September of
around $ 64.4 M or $ 2.46
per share.
We estimated VNDA's net
cash value to be
around $ 38.6 M or $ 1.45
per share, and believed that the investment turned on TCP's ability to get control of the board at the Annual Meeting.
We last estimated the net
cash liquidation value at
around $ 34M or $ 1.14
per share.
Following the payment of the special dividend, SOAP has
cash of
around $ 17.5 M or a little over $ 1.00
per share.
We last estimated the net
cash value at
around $ 32.2 M or $ 1.23
per share and the liquidation value at
around $ 43.4 M or $ 1.65
per share.
We initially estimated CRGN's net
cash value to be
around $ 62M or $ 1.07
per share.
We estimate AVGN's
cash at
around $ 1.22
per share (BVF estimates $ 1.20
per share), which is a little less than 15 % higher than AVGN's $ 1.05 close yesterday.
We estimate the liquidation value to be
around $ 28.4 M or $ 0.86 and the net
cash value to be
around $ 27.7 M or $ 0.86
per share.
AVGN's board is developing a plan of liquidation, which should put a floor on AVGN's stock at
around its net
cash value of $ 34M or $ 1.14
per share less wind down costs.
If we assume that NSTR used
around $ 4M in
cash last quarter and it costs circa $ 2M to wind up the company, we estimate it will pay out
around $ 59.1 M or $ 2.26
per share.
The programme has a budget of
around $ 15 billion,
shared between 35 countries — or very roughly $ 12 million
per year,
per country on average — barely enough
cash to finance a small wind farm.
The two firms have agreed on a
cash and
shares offer from Shell that will pay BG Group shareholders
around 1,350 p
per share — a 50 % premium on BG Group's
share price on Tuesday (7 April).